249 related articles for article (PubMed ID: 28465473)
1. Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis.
Yu JH; Kim JM; Kim JK; Choi SJ; Lee KS; Lee JW; Chang HY; Lee JI
Oncotarget; 2017 Jun; 8(24):39534-39546. PubMed ID: 28465473
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma.
Wei T; Zhang LN; Lv Y; Ma XY; Zhi L; Liu C; Ma F; Zhang XF
Oncotarget; 2014 Nov; 5(21):10307-17. PubMed ID: 25333264
[TBL] [Abstract][Full Text] [Related]
3. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma.
Govaere O; Petz M; Wouters J; Vandewynckel YP; Scott EJ; Topal B; Nevens F; Verslype C; Anstee QM; Van Vlierberghe H; Mikulits W; Roskams T
Oncogene; 2017 Nov; 36(47):6605-6616. PubMed ID: 28783171
[TBL] [Abstract][Full Text] [Related]
4. Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer.
Stock P; Monga D; Tan X; Micsenyi A; Loizos N; Monga SP
Mol Cancer Ther; 2007 Jul; 6(7):1932-41. PubMed ID: 17604334
[TBL] [Abstract][Full Text] [Related]
5. Selective deletion of hepatocyte platelet-derived growth factor receptor α and development of liver fibrosis in mice.
Lim BJ; Lee WK; Lee HW; Lee KS; Kim JK; Chang HY; Lee JI
Cell Commun Signal; 2018 Dec; 16(1):93. PubMed ID: 30509307
[TBL] [Abstract][Full Text] [Related]
6. Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.
Patel SH; Kneuertz PJ; Delgado M; Kooby DA; Staley CA; El-Rayes BF; Kauh JS; Sarmiento JM; Hanish S; Cohen C; Farris AB; Maithel SK
Ann Surg Oncol; 2011 Nov; 18(12):3384-90. PubMed ID: 21590454
[TBL] [Abstract][Full Text] [Related]
7. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study.
Chun YS; Huang M; Rink L; Von Mehren M
World J Surg Oncol; 2014 Jul; 12():231. PubMed ID: 25052889
[TBL] [Abstract][Full Text] [Related]
8. MBD2 as a novel marker associated with poor survival of patients with hepatocellular carcinoma after hepatic resection.
Liu W; Wang N; Lu M; Du XJ; Xing BC
Mol Med Rep; 2016 Aug; 14(2):1617-23. PubMed ID: 27315121
[TBL] [Abstract][Full Text] [Related]
9. Activation of platelet-derived growth factor receptor alpha contributes to liver fibrosis.
Hayes BJ; Riehle KJ; Shimizu-Albergine M; Bauer RL; Hudkins KL; Johansson F; Yeh MM; Mahoney WM; Yeung RS; Campbell JS
PLoS One; 2014; 9(3):e92925. PubMed ID: 24667490
[TBL] [Abstract][Full Text] [Related]
10. Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma.
Chen L; Shi Y; Jiang CY; Wei LX; Lv YL; Wang YL; Dai GH
Int J Biol Markers; 2011; 26(2):108-16. PubMed ID: 21574155
[TBL] [Abstract][Full Text] [Related]
11. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients.
Chen YL; Lin PY; Ming YZ; Huang WC; Chen RF; Chen PM; Chu PY
BMC Cancer; 2017 Jul; 17(1):474. PubMed ID: 28687090
[TBL] [Abstract][Full Text] [Related]
12. Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.
Wang P; Guo L; Li K; Ning S; Shi W; Liu Z; Chen Y
Cancer Biomark; 2018 Feb; 21(3):681-687. PubMed ID: 29278882
[TBL] [Abstract][Full Text] [Related]
13. The prognostic value of combined TGF-β1 and ELF in hepatocellular carcinoma.
Ji F; Fu SJ; Shen SL; Zhang LJ; Cao QH; Li SQ; Peng BG; Liang LJ; Hua YP
BMC Cancer; 2015 Mar; 15():116. PubMed ID: 25880619
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis.
Jin B; Gong Z; Yang N; Huang Z; Zeng S; Chen H; Hu S; Pan G
Tumour Biol; 2016 May; 37(5):5911-7. PubMed ID: 26592251
[TBL] [Abstract][Full Text] [Related]
15. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis.
Campbell JS; Johnson MM; Bauer RL; Hudkins KL; Gilbertson DG; Riehle KJ; Yeh MM; Alpers CE; Fausto N
Differentiation; 2007 Nov; 75(9):843-52. PubMed ID: 17999742
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of AGGF1 is correlated with angiogenesis and poor prognosis of hepatocellular carcinoma.
Wang W; Li GY; Zhu JY; Huang DB; Zhou HC; Zhong W; Ji CS
Med Oncol; 2015 Apr; 32(4):131. PubMed ID: 25796501
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis.
Giannini EG; Marenco S; Borgonovo G; Savarino V; Farinati F; Del Poggio P; Rapaccini GL; Anna Di Nolfo M; Benvegnù L; Zoli M; Borzio F; Caturelli E; Chiaramonte M; Trevisani F;
Hepatology; 2012 Oct; 56(4):1371-9. PubMed ID: 22535689
[TBL] [Abstract][Full Text] [Related]
18. Decreased STAT4 indicates poor prognosis and enhanced cell proliferation in hepatocellular carcinoma.
Wang G; Chen JH; Qiang Y; Wang DZ; Chen Z
World J Gastroenterol; 2015 Apr; 21(13):3983-93. PubMed ID: 25852285
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma.
Dai B; Ruan B; Wu J; Wang J; Shang R; Sun W; Li X; Dou K; Wang D; Li Y
Int J Clin Exp Pathol; 2014; 7(9):5645-54. PubMed ID: 25337205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
